We are live on ! Find out more
KZR

Kezar Life Sciences

Delisted

KZR was delisted on the 8th of May, 2026.

55 hedge funds and large institutions have $36.8M invested in Kezar Life Sciences in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 15

19% more capital invested

Capital invested by funds: $30.9M → $36.8M (+$5.87M)

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

2% more funds holding

Funds holding: 5455 (+1)

0.13% less ownership

Funds ownership: 4.92%4.79% (-0.13%)

Holders
55
Holders Change
+1
Holders Change %
+1.85%
% of All Funds
1.08%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
22
Reduced
15
Closed
8
Calls
Puts
Net Calls
Net Calls Change

KZR Hedge Fund Activity: Q4 2019 in Review

55 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q4 2019, worth a combined $36.8M — up 19% from $30.9M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new KZR positions and 8 closed out — a net gain of 1 holder — while 22 added to existing stakes and 15 trimmed.

The largest buyer was Bellevue Group, adding an estimated $985K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $3.04M sold.

  • 55 institutional investors held Kezar Life Sciences (KZR) as of Q4 2019, up from 54 in Q3 2019.
  • Funds reported $36.8M of Kezar Life Sciences stock for Q4 2019, up 19% quarter-over-quarter.
  • 9 funds opened new Kezar Life Sciences positions in Q4 2019 and 8 closed out, a net change of +1 holder.
  • The largest Kezar Life Sciences buyer in Q4 2019 was Bellevue Group, an estimated $985K added.
  • The largest Kezar Life Sciences seller in Q4 2019 was Cormorant Asset Management, an estimated $3.04M sold.

Based on aggregated 13F filings for Q4 2019.